| 书目名称 | New Targets in Inflammation |
| 副标题 | Inhibitors of COX-2 |
| 编辑 | Nicolas Bazan,Jack Botting,John Vane |
| 视频video | http://file.papertrans.cn/666/665791/665791.mp4 |
| 图书封面 |  |
| 描述 | For the past 100 years the mainstay of therapy for rheumatoid arthritis (RA) has been aspirin or other drugs of the non-steroid anti-inflammatory group. In 1971 Vane pro posed that both the beneficial and toxic actions of these drugs was through inhibition of prostaglandin synthesis. The recent discovery that prostaglandins responsible for pain and other symptoms at inflammatory foci are synthesized by an inducible cyclooxygenase (COX-2) that is encoded by a gene distinct from that of the consti tutive enzyme (COX-I) provided a new target for therapy of RA. A drug that would selectively inhibit COX-2 would hopefully produce the symptomatic benefit provided by existing NSAIDs without the gastrointestinal and renal toxicity due to the inhibition of COX-I. Drugs selective for COX-2 are now available. Experimental studies have shown them to be effective with minimal toxicity, and in clinical trials gastric and renal toxicities are less. Highly selective COX-2 inhibitors, perhaps designed with knowledge of the crystal structures of COX-I and COX-2, are also available. Other experimental studies, including those in animals lacking effective genes for COX-lor COX-2 and in experimental c |
| 出版日期 | Conference proceedings 1996 |
| 关键词 | Prostaglandin; cancer; cytokine; inflammation; research |
| 版次 | 1 |
| doi | https://doi.org/10.1007/978-94-011-5386-7 |
| isbn_softcover | 978-94-010-6265-7 |
| isbn_ebook | 978-94-011-5386-7 |
| copyright | Springer Science+Business Media Dordrecht 1996 |
|Archiver|手机版|小黑屋|
派博传思国际
( 京公网安备110108008328)
GMT+8, 2025-8-24 23:44
发表于 2025-3-21 16:59:46
